Sie sind auf Seite 1von 1

Buscopan

Drug Classes
Antispasmodic
Anticholinergic
Therapeutic Actions
Hyoscine-N-butylbromide (HNBB) acts by interfering with the transmission of nerv
e impulses by acetylcholine in the parasympathetic nervous system.
Buscopan exerts a spasmolytic action on the smooth muscle of the gastrointestina
l, biliary and urinary tracts. As a quaternary ammonium derivative, hyoscine-Nbutylbromide does not enter the central nervous system. Therefore, anticholinerg
ic side effects at the central nervous system do not occur. Peripheral anticholi
nergic effects result from a ganglion-blocking action within the visceral wall a
s well as from anti- muscarinic activity.
Indications
Buscopan Tablets are indicated for the relief of spasm of the genito-urinary tra
ct or gastro- intestinal tract and for the symptomatic relief of Irritable Bowel
Syndrome
Presentation & Administration
Intravenous (IV)
20mg in 1ml (solution)
Dilute required dose to 10ml with normal saline. Inject slowly over 3-5 minutes.
Compatible with the following IV fluids:
Normal saline, 5% glucose glucose and sodium chloride
May be given into the side arm when the above IV fluids are being infused. Store
at room temperature. Protect from light.
IM or SC:
Inject undiluted into a large muscle mass or subcutaneously
Per-orem
Buscopan 10mg (white)
Gastro-Soothe 10mg (white)
Contraindications
Buscopan Tablets should not be administered to patients with myasthenia gravis,
megacolon and narrow angle glaucoma. In addition, they should not be given to pa
tients with a known hypersensitivity to hyoscine-N-butylbromide or any other com
ponent of the product.
Adverse Effects
CNS: dizziness, anaphylactic reactions, anaphylactic shock, increased ICP, disor
ientation, restlessness, irritability, dizziness, drowsiness, headache, confusio
n, hallucination, delirium, impaired memory
CV: hypotension, tachycardia, palpitations, flushing
GI: Dry mouth, constipation, nausea, epigastric distress
DERM: flushing, dyshidrosis
GU: Urinary retention, urinary hesitancy
Resp: dyspnea, bronchial plugging, depressed respiration
EENT: mydriasis, dilated pupils, blurred vision, photopobia, increased intraocul
ar pressure, difficulty of swallowing.
Nursing Considerations
Drug compatibility should be monitored closely in patients requiring adjunctive
therapy
Avoid driving & operating machinery after parenteral administration.
Avoid strict heat
Raise side rails as a precaution because some patients become temporarily excite
d or disoriented and some develop amnesia or become drowsy.
Reorient patient, as needed, Tolerance may develop when therapy is prolonged
Atropine-like toxicity may cause dose related adverse reactions. Individual tole
rance varies greatly
Oerdose may cause curare-like effects, such as respiratory paralysis. Keep emerg
ency equipment available.